Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic Keating

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Chest|November 11, 2023
Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension TherapyKatherine Kearney, Karen Brown, David S Celermajer, et al.
Respirology (Carlton, Vic.)|January 31, 2020
Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registryVictor Khou, James J Anderson, Geoff Strange, et al.
Respirology (Carlton, Vic.)|October 5, 2021
Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registryKatherine Kearney, Joshua Gold, Carolyn Corrigan, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
Chest|September 30, 2019
Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry CohortJames J Anderson, Edmund M Lau, Melanie Lavender, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosisEva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Chest|November 11, 2023
Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension TherapyKatherine Kearney, Karen Brown, David S Celermajer, et al.
Respirology (Carlton, Vic.)|January 31, 2020
Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registryVictor Khou, James J Anderson, Geoff Strange, et al.
Respirology (Carlton, Vic.)|October 5, 2021
Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registryKatherine Kearney, Joshua Gold, Carolyn Corrigan, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
Chest|September 30, 2019
Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry CohortJames J Anderson, Edmund M Lau, Melanie Lavender, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosisEva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Pageof 3